Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...
Myriad Genetics, Inc., is a leading precision m...
Apollo Endosurgery, Inc. is a medical device company focused on less invasive ther...
Apollo Endosurgery, Inc. is a medical device co...
Emisphere Technologies is a Drug Delivery Company whose core business strategy is ...
Emisphere Technologies is a Drug Delivery Compa...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
Join the National Investor Network and get the latest information with your interests in mind.